Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 50

1.

Function, essentiality, and expression of cytochrome P450 enzymes and their cognate redox partners in Mycobacterium tuberculosis: are they drug targets?

Ortega Ugalde S, Boot M, Commandeur JNM, Jennings P, Bitter W, Vos JC.

Appl Microbiol Biotechnol. 2019 May;103(9):3597-3614. doi: 10.1007/s00253-019-09697-z. Epub 2019 Feb 27. Review.

2.

Targeting the ribosome biogenesis key molecule fibrillarin to avoid chemoresistance.

El Hassouni B, Sarkisjan D, Vos JC, Giovannetti E, Peters GJ.

Curr Med Chem. 2018 Dec 3. doi: 10.2174/0929867326666181203133332. [Epub ahead of print]

PMID:
30501594
3.

Linking cytochrome P450 enzymes from Mycobacterium tuberculosis to their cognate ferredoxin partners.

Ortega Ugalde S, de Koning CP, Wallraven K, Bruyneel B, Vermeulen NPE, Grossmann TN, Bitter W, Commandeur JNM, Vos JC.

Appl Microbiol Biotechnol. 2018 Nov;102(21):9231-9242. doi: 10.1007/s00253-018-9299-4. Epub 2018 Aug 22.

4.

Acetaminophen reduces the protein levels of high affinity amino acid permeases and causes tryptophan depletion.

Huseinovic A, Dekker SJ, Boogaard B, Vermeulen NPE, Kooter JM, Vos JC.

Amino Acids. 2018 Oct;50(10):1377-1390. doi: 10.1007/s00726-018-2613-8. Epub 2018 Jul 5.

5.

A combined computational and experimental study on selective flucloxacillin hydroxylation by cytochrome P450 BM3 variants.

Luirink RA, Dekker SJ, Capoferri L, Janssen LFH, Kuiper CL, Ari ME, Vermeulen NPE, Vos JC, Commandeur JNM, Geerke DP.

J Inorg Biochem. 2018 Jul;184:115-122. doi: 10.1016/j.jinorgbio.2018.04.013. Epub 2018 Apr 24.

PMID:
29723739
6.

Glutathione S-Transferase P1 Protects Against Amodiaquine Quinoneimines-Induced Cytotoxicity but Does Not Prevent Activation of Endoplasmic Reticulum Stress in HepG2 Cells.

Zhang Y, den Braver-Sewradj SP, den Braver MW, Hiemstra S, Vermeulen NPE, van de Water B, Commandeur JNM, Vos JC.

Front Pharmacol. 2018 Apr 18;9:388. doi: 10.3389/fphar.2018.00388. eCollection 2018.

7.

Inter-individual Variability in Activity of the Major Drug Metabolizing Enzymes in Liver Homogenates of 20 Individuals.

den Braver-Sewradj SP, den Braver MW, van Dijk M, Zhang Y, Dekker SJ, Wijaya L, Vermeulen NPE, Richert L, Commandeur JNM, Vos JC.

Curr Drug Metab. 2018;19(4):370-381. doi: 10.2174/1389200219666180108160046.

PMID:
29318967
8.

Reduction and Scavenging of Chemically Reactive Drug Metabolites by NAD(P)H:Quinone Oxidoreductase 1 and NRH:Quinone Oxidoreductase 2 and Variability in Hepatic Concentrations.

den Braver-Sewradj SP, den Braver MW, Toorneman RM, van Leeuwen S, Zhang Y, Dekker SJ, Vermeulen NPE, Commandeur JNM, Vos JC.

Chem Res Toxicol. 2018 Feb 19;31(2):116-126. doi: 10.1021/acs.chemrestox.7b00289. Epub 2018 Jan 11.

9.

Drug toxicity profiling of a Saccharomyces cerevisiae deubiquitinase deletion panel shows that acetaminophen mimics tyrosine.

Huseinovic A, van Dijk M, Vermeulen NPE, van Leeuwen F, Kooter JM, Vos JC.

Toxicol In Vitro. 2018 Mar;47:259-268. doi: 10.1016/j.tiv.2017.12.007. Epub 2017 Dec 16.

10.

Direct comparison of UDP-glucuronosyltransferase and cytochrome P450 activities in human liver microsomes, plated and suspended primary human hepatocytes from five liver donors.

den Braver-Sewradj SP, den Braver MW, Baze A, Decorde J, Fonsi M, Bachellier P, Vermeulen NPE, Commandeur JNM, Richert L, Vos JC.

Eur J Pharm Sci. 2017 Nov 15;109:96-110. doi: 10.1016/j.ejps.2017.07.032. Epub 2017 Aug 1.

PMID:
28778465
11.

Human glutathione S-transferases- and NAD(P)H:quinone oxidoreductase 1-catalyzed inactivation of reactive quinoneimines of amodiaquine and N-desethylamodiaquine: Possible implications for susceptibility to amodiaquine-induced liver toxicity.

Zhang Y, den Braver-Sewradj SP, Vos JC, Vermeulen NPE, Commandeur JNM.

Toxicol Lett. 2017 Jun 5;275:83-91. doi: 10.1016/j.toxlet.2017.05.003. Epub 2017 May 3.

PMID:
28478157
12.

The effect of acetaminophen on ubiquitin homeostasis in Saccharomyces cerevisiae.

Huseinovic A, van Leeuwen JS, van Welsem T, Stulemeijer I, van Leeuwen F, Vermeulen NP, Kooter JM, Vos JC.

PLoS One. 2017 Mar 14;12(3):e0173573. doi: 10.1371/journal.pone.0173573. eCollection 2017.

13.

Different Reactive Metabolites of Nevirapine Require Distinct Glutathione S-Transferase Isoforms for Bioinactivation.

Dekker SJ, Zhang Y, Vos JC, Vermeulen NP, Commandeur JN.

Chem Res Toxicol. 2016 Dec 19;29(12):2136-2144. Epub 2016 Nov 28.

PMID:
27989146
14.

Eplerenone does not limit ischemia-reperfusion injury in human myocardial tissue.

van den Berg TN, van Swieten HA, Vos JC, Verweij V, Wouterse AC, Deinum J, Morshuis WJ, Rongen GA, Riksen NP.

Int J Cardiol. 2016 Aug 1;216:110-3. doi: 10.1016/j.ijcard.2016.04.150. Epub 2016 Apr 22. No abstract available.

15.

Inter-donor variability of phase I/phase II metabolism of three reference drugs in cryopreserved primary human hepatocytes in suspension and monolayer.

den Braver-Sewradj SP, den Braver MW, Vermeulen NP, Commandeur JN, Richert L, Vos JC.

Toxicol In Vitro. 2016 Jun;33:71-9. doi: 10.1016/j.tiv.2016.02.013. Epub 2016 Feb 26.

PMID:
26921663
16.

Sunitinib does not attenuate contractile force following a period of ischemia in isolated human cardiac muscle.

Thijs AM, El Messaoudi S, Vos JC, Wouterse AC, Verweij V, van Swieten H, van Herpen CM, van der Graaf WT, Noyez L, Rongen GA.

Target Oncol. 2015 Sep;10(3):439-43. doi: 10.1007/s11523-014-0351-8. Epub 2014 Dec 23.

PMID:
25529578
17.

Activation of the anticancer drugs cyclophosphamide and ifosfamide by cytochrome P450 BM3 mutants.

Vredenburg G, den Braver-Sewradj S, van Vugt-Lussenburg BM, Vermeulen NP, Commandeur JN, Vos JC.

Toxicol Lett. 2015 Jan 5;232(1):182-92. doi: 10.1016/j.toxlet.2014.11.005. Epub 2014 Nov 6.

PMID:
25448283
18.

Human NAD(P)H:quinone oxidoreductase 1 (NQO1)-mediated inactivation of reactive quinoneimine metabolites of diclofenac and mefenamic acid.

Vredenburg G, Elias NS, Venkataraman H, Hendriks DF, Vermeulen NP, Commandeur JN, Vos JC.

Chem Res Toxicol. 2014 Apr 21;27(4):576-86. doi: 10.1021/tx400431k. Epub 2014 Feb 26.

PMID:
24552538
19.

Reconstitution of the interplay between cytochrome P450 and human glutathione S-transferases in clozapine metabolism in yeast.

Vredenburg G, Vassell KP, Commandeur JN, Vermeulen NP, Vos JC.

Toxicol Lett. 2013 Oct 9;222(3):247-56. doi: 10.1016/j.toxlet.2013.07.023. Epub 2013 Aug 2.

PMID:
23916688
20.

Differential involvement of mitochondrial dysfunction, cytochrome P450 activity, and active transport in the toxicity of structurally related NSAIDs.

van Leeuwen JS, Unlü B, Vermeulen NP, Vos JC.

Toxicol In Vitro. 2012 Mar;26(2):197-205. doi: 10.1016/j.tiv.2011.11.013. Epub 2011 Nov 26.

PMID:
22138569
21.

Involvement of the pleiotropic drug resistance response, protein kinase C signaling, and altered zinc homeostasis in resistance of Saccharomyces cerevisiae to diclofenac.

van Leeuwen JS, Vermeulen NP, Vos JC.

Appl Environ Microbiol. 2011 Sep;77(17):5973-80. doi: 10.1128/AEM.00253-11. Epub 2011 Jul 1.

22.

Subunits Rip1p and Cox9p of the respiratory chain contribute to diclofenac-induced mitochondrial dysfunction.

van Leeuwen JS, Orij R, Luttik MA, Smits GJ, Vermeulen NP, Vos JC.

Microbiology. 2011 Mar;157(Pt 3):685-94. doi: 10.1099/mic.0.044578-0. Epub 2010 Dec 9.

PMID:
21148204
23.

Metabolism related toxicity of diclofenac in yeast as model system.

van Leeuwen JS, Vredenburg G, Dragovic S, Tjong TF, Vos JC, Vermeulen NP.

Toxicol Lett. 2011 Feb 5;200(3):162-8. doi: 10.1016/j.toxlet.2010.11.010. Epub 2010 Nov 24.

PMID:
21111035
24.

Myeloid leukemic progenitor cells can be specifically targeted by minor histocompatibility antigen LRH-1-reactive cytotoxic T cells.

Norde WJ, Overes IM, Maas F, Fredrix H, Vos JC, Kester MG, van der Voort R, Jedema I, Falkenburg JH, Schattenberg AV, de Witte TM, Dolstra H.

Blood. 2009 Mar 5;113(10):2312-23. doi: 10.1182/blood-2008-04-153825. Epub 2008 Dec 12.

PMID:
19074734
25.

Aberrant expression of the hematopoietic-restricted minor histocompatibility antigen LRH-1 on solid tumors results in efficient cytotoxic T cell-mediated lysis.

Overes IM, Levenga TH, Vos JC, van Horssen-Zoetbrood A, van der Voort R, De Mulder PH, de Witte TM, Dolstra H.

Cancer Immunol Immunother. 2009 Mar;58(3):429-39. doi: 10.1007/s00262-008-0569-3. Epub 2008 Aug 22.

PMID:
18719914
26.

The B cell antigen receptor controls AP-1 and NFAT activity through Ras-mediated activation of Ral.

de Gorter DJ, Vos JC, Pals ST, Spaargaren M.

J Immunol. 2007 Feb 1;178(3):1405-14.

27.

Slx9p facilitates efficient ITS1 processing of pre-rRNA in Saccharomyces cerevisiae.

Bax R, Raué HA, Vos JC.

RNA. 2006 Nov;12(11):2005-13. Epub 2006 Oct 3.

28.

5'-end formation of yeast 5.8SL rRNA is an endonucleolytic event.

Faber AW, Vos HR, Vos JC, Raué HA.

Biochem Biophys Res Commun. 2006 Jun 30;345(2):796-802. Epub 2006 May 5.

PMID:
16701559
29.
30.
32.
33.

U3 snoRNP and Rrp5p associate independently with Saccharomyces cerevisiae 35S pre-rRNA, but Rrp5p is essential for association of Rok1p.

Vos HR, Bax R, Faber AW, Vos JC, Raué HA.

Nucleic Acids Res. 2004 Nov 2;32(19):5827-33. Print 2004.

34.

Rio2p, an evolutionarily conserved, low abundant protein kinase essential for processing of 20 S Pre-rRNA in Saccharomyces cerevisiae.

Geerlings TH, Faber AW, Bister MD, Vos JC, Raué HA.

J Biol Chem. 2003 Jun 20;278(25):22537-45. Epub 2003 Apr 10.

35.

Deletions in the S1 domain of Rrp5p cause processing at a novel site in ITS1 of yeast pre-rRNA that depends on Rex4p.

Eppens NA, Faber AW, Rondaij M, Jahangir RS, van Hemert S, Vos JC, Venema J, Raué HA.

Nucleic Acids Res. 2002 Oct 1;30(19):4222-31.

36.
37.
38.

The major substrates for TAP in vivo are derived from newly synthesized proteins.

Reits EA, Vos JC, Grommé M, Neefjes J.

Nature. 2000 Apr 13;404(6779):774-8.

PMID:
10783892
39.

Head-head/tail-tail relative orientation of the pore-forming domains of the heterodimeric ABC transporter TAP.

Vos JC, Reits EA, Wojcik-Jacobs E, Neefjes J.

Curr Biol. 2000 Jan 13;10(1):1-7.

40.
41.

Transposase is the only nematode protein required for in vitro transposition of Tc1.

Vos JC, De Baere I, Plasterk RH.

Genes Dev. 1996 Mar 15;10(6):755-61.

42.
43.

Characterization of the Caenorhabditis elegans Tc1 transposase in vivo and in vitro.

Vos JC, van Luenen HG, Plasterk RH.

Genes Dev. 1993 Jul;7(7A):1244-53.

44.

In vitro recognition of an orf virus early promoter in a vaccinia virus extract.

Vos JC, Mercer AA, Fleming SB, Robinson AJ.

Arch Virol. 1992;123(1-2):223-8.

PMID:
1312824
45.

Vaccinia virus capping enzyme is a transcription initiation factor.

Vos JC, Sasker M, Stunnenberg HG.

EMBO J. 1991 Sep;10(9):2553-8.

46.
47.

Mutational analysis of a vaccinia virus intermediate promoter in vivo and in vitro.

Hirschmann P, Vos JC, Stunnenberg HG.

J Virol. 1990 Dec;64(12):6063-9.

48.
49.

Discontinuous transcription or RNA processing of vaccinia virus late messengers results in a 5' poly(A) leader.

Schwer B, Visca P, Vos JC, Stunnenberg HG.

Cell. 1987 Jul 17;50(2):163-9.

PMID:
3594569
50.

[Death caused by one tablet of Burgodin].

de Vos JC, Rohof OJ, Bernsen PJ, Conemans JM, van Unnik AJ.

Ned Tijdschr Geneeskd. 1983 Aug 20;127(34):1552-3. Dutch. No abstract available.

PMID:
6633692

Supplemental Content

Support Center